Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline versus intravenous calcium gluconate for prevention of ovarian hyperstimulation in women with polycystic ovarian disease undergoing ICSI
ACTRN12613000904774Phase 4Recruiting
- Sponsor
- Eman Elkattan
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cabergoline and calcium gluconate in ovarian hyperstimulation syndrome (OHSS), sponsored by Eman Elkattan. Primary endpoints: Occurrence of ovarian hyperstimulation and Severity of ovarian hyperstimulation. Started Jul 2013; status: recruiting.
02
Drugs
cabergolinecalcium gluconate
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on ACTRN12613000904774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000904774.